Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
Compounded GLP
The vial reads 10mg/mL
One suggested practice to managing GI AEs is the Three Es method, which comprises 1) education and explanation, 2) escalation to an appropriate dose, and 3) effective management of GI AEs
Licensing (Marketing Authorisation): The MHRA has approved: Semaglutide (Wegovy) for adults with BMI 30 kg/m or BMI 27 kg/m with at least one weight-related comorbidity Liraglutide (Saxenda) with similar BMI criteria NHS Access (NICE Guidance): According to NICE guidance (TA664 for semaglutide), NHS-funded treatment is more restricted and typically available for adults with: BMI 35 kg/m with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease) For individuals from Black, Asian, and minority ethnic backgrounds, lower BMI thresholds may apply, recognising that these populations face increased metabolic risk at lower BMI levels
